Norway · Delayed Price · Currency is NOK Nykode Therapeutics AS Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw strong clinical progress, notably with abisuvva's superior response rates in head and neck cancer and new patents for the VB10.NEO platform. Operating expenses fell sharply, with a solid cash runway into 2028 and key trial milestones expected in 2026-2027.
-
Advanced lead cancer immunotherapy into phase II, secured new patents for neoantigen platform, and demonstrated strong preclinical results for autoimmune tolerance. Reduced operating expenses and maintained a strong cash position, with a runway into 2028 and key data readouts expected in 2026–2027.
-
Q2 2025 saw a strategic pivot to focus on VB10.16 in head and neck cancer, with a new phase II trial planned and strong supporting data. Operating expenses dropped sharply, resulting in a net profit and a $70M cash position. Cash runway extends into 2028, supporting key inflection points.
-
Organizational streamlining and cost control improved financials, with a reduced net loss and strong cash position. Key clinical and preclinical data for VB10.16, VB10.NEO, and the immune tolerance platform support continued development, with strategic updates expected in Q2 2025.
Fiscal Year 2024
-
Strategic refocus and cost reductions have extended the cash runway into 2030, with a strong cash position and a targeted annual cost base of $20 million. Key programs showed strong clinical and preclinical results, and the company is actively pursuing partnerships and further guidance on its pipeline.
-
A major strategic refocus will reduce costs by 50%, extend cash runway into 2030, and prioritize research and early partnerships. Clinical progress continues for VB10.16 and VB10.NEO, with strong cash and equity positions supporting the transition.
-
Genentech is terminating its VB10.NEO partnership, returning full control and IP to Nykode, with no impact from clinical data or technology issues. Nykode will explore new strategic options for VB10.NEO, maintain cost discipline, and remains confident in its pipeline and financial position.
-
Strategic focus shifted to locally advanced cervical cancer and head and neck cancer, discontinuing VB-C-04 due to recruitment challenges. Q2 net loss was $7.4M, with a strong cash position and ongoing partnerships with Genentech and Regeneron. Key U.S. patent granted for neoantigen vaccines.